• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Amazon Contemplating Lawsuit Against Surescripts

Share:

July 29, 2019

Surescripts is seeking to cut off PillPack’s access to patient data, and the latter, an Amazon-owned company, isn’t taking the matter lightly.

Last week, it was reported that Amazon is contemplating a lawsuit against electronic prescribing company Surescripts, which has taken action to prevent the former from accessing its patient information. A lawsuit could complicate matters for both businesses.

This comes about a year after Amazon snatched up PillPack in a $753 million acquisition. PillPack, a pharmacy delivery service, receives comprehensive data indirectly from Surescripts, and uses the information to access patient medication lists, inform patients about potential safety risks, pinpoint duplicate medications and assist with refills. Surescripts is owned by potential PillPack competitors CVS and Express Scripts.

According to a CNBC report, PillPack will soon be blocked from accessing that data from third party company ReMy Health. Amazon’s pending lawsuit is designed to put the brakes on those efforts, with PIllPack allegedly sending a cease-and-desist letter to Surescripts.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Rather than contracting directly with Surescripts, Pillpack goes through ReMy for information on patient medication. ReMy collects raw data from Surescripts and sends a more polished version of it to clients through its application software. ReMy indicated last week that it would cease working with Pillpack, severing a relationship that began in 2017.

WHAT’S THE IMPACT

If PillPack loses access to data from Surescripts it would effectively be cut off from patients’ digital histories. This introduces a particularly vexing challenge, since many of its patients take multiple medications prescribed by various doctors. PillPack would probably have to call each patient by phone to get their medication lists, a time-consuming process that would rely on patients’ memories rather than on hard and fast data.

There’s another possible complication for Amazon. According to a Forbes contributor, if Amazon goes forward with the lawsuit, it may be hit by claims for openness on its own part — adding stress to its practice of keeping a private lid on its own customer data.

Amazon told Forbes this was an unfounded concern, given the differences between customer data and personal health information.

THE LARGER TREND

Amazon reported $3.6 billion in profit for the first quarter of 2019, more than double the $1.6 billion earned during the same time period last year, releasing its quarterly report during the same week it began actively marketing PillPack to its customers.

Date: July 29, 2019

Source: Healthcare Finance

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Zoll Medical Corporation Acquires TherOx, Inc.Zoll Medical Corporation Acquires TherOx, Inc.
  • Baze’s Personalized Nutrition Supplement Service Closes $6M Series ABaze’s Personalized Nutrition Supplement Service Closes $6M Series A
  • Biosynth Carbosynth Further Expands Life Sciences Platform with Acquisition of Aalto Bio ReagentsBiosynth Carbosynth Further Expands Life Sciences Platform with Acquisition of Aalto Bio Reagents
  • Global Thymopentin Market 2020 Industry Scenario, Strategies, Growth Factors and Forecast to 2025Global Thymopentin Market 2020 Industry Scenario, Strategies, Growth Factors and Forecast to 2025
  • Why Now Is The Time to Reimagine Healthcare Through TechnologyWhy Now Is The Time to Reimagine Healthcare Through Technology
  • Nova Research Laboratories, LLC Announces Acquisition of CiPA LabNova Research Laboratories, LLC Announces Acquisition of CiPA Lab
  • Stimwave Announces Sale of BusinessStimwave Announces Sale of Business
  • Sorrento Enters Into Letter Of Intent To Acquire SmartPharm And Develop Pipeline Of Gene-Encoded Therapeutic Antibodies, Starting With Neutralizing Antibodies To Treat COVID-19 and Cancer TherapeuticsSorrento Enters Into Letter Of Intent To Acquire SmartPharm And Develop Pipeline Of Gene-Encoded Therapeutic Antibodies, Starting With Neutralizing Antibodies To Treat COVID-19 and Cancer Therapeutics

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications